Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: September 5, 2006
Last updated: June 5, 2012
Last verified: June 2012
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

Condition Intervention Phase
Carcinoma, Renal Cell
Drug: CP-675,206
Drug: SU011248
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To determine the highest tolerable dose of CP-675,206 that can be combined with SU011248. The safety observation period will be 6 weeks from the first dose of study drug [ Time Frame: 6 weeks after first dose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To allow for the possibility of genotyping should an unexpected outcome or an increase in unexplained adverse events be reported [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To evaluate the pharmacokinetics (PK) of CP-675,206 and SU011248 when given in combination [ Time Frame: up to 18 months ] [ Designated as safety issue: No ]
  • To monitor for an antibody response to CP-675,206 [ Time Frame: up to 18 months ] [ Designated as safety issue: No ]
  • To assess any preliminary evidence of anti-tumor activity: 6-18 months after last subject enrolled [ Time Frame: 6-18 months after last subject enrolled ] [ Designated as safety issue: No ]

Enrollment: 28
Study Start Date: November 2006
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A Drug: CP-675,206
CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
Drug: SU011248
SU011248 administered at a dose of 37.5mg/day every day.
Experimental: Arm B Drug: CP-675,206
CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
Drug: SU011248
SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven renal cell carcinoma with metastases
  • Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

Exclusion Criteria:

  • Prior treatment with more than one systemic therapy for metastatic renal cell carcinoma
  • History of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00372853

United States, Arizona
Research Site
Scottsdale, Arizona, United States, 85258
United States, New Jersey
Research Site
New Brunswick, New Jersey, United States, 08903
United States, Ohio
Research Site
Cleveland, Ohio, United States, 44195
United States, South Carolina
Research Site
Greenville, South Carolina, United States, 29605
United States, Tennessee
Research Site
Memphis, Tennessee, United States, 38120
Sponsors and Collaborators
  More Information

Responsible Party: AstraZeneca Identifier: NCT00372853     History of Changes
Other Study ID Numbers: A3671025 
Study First Received: September 5, 2006
Last Updated: June 5, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Diseases
Kidney Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on May 01, 2016